Oxaliplatin: A review of evolving concepts

Cancer Investigation

Volumn 20, Issue 2, 2002, Pages 246-263

  Mani, Sridhar ^a   Graham, Martin A ^b   Bregman, David B ^a   Ivy, Percy ^c   Chaney, Stephen G ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Sanofi Synthelabo ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NOLATREXED; OXALIPLATIN; PACLITAXEL; RALTITREXED; TETRAPLATIN; TOPOTECAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 0036188793     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120001152     Document Type: Review

References (176)

1. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia
2. Role of carrier ligand in platinum resistance in L1210 cells
3. Role of carrier ligand in platinum resistance of human carcinoma cell lines
4. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
5. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes
6. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality
7. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells
8. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
9. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin
10. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) dGpG intrastrand cross-link, the major adduct of the anticancer drug cisplatin
11. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
12. Excision repair in mammalian cells
13. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-amine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts
14. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity
15. The role of mismatch repair in platinum drug resistance
16. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
17. 2-terminal kinase and c-Ab1 kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin
18. Induction of JNK and c-Ab1 signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
19. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells
20. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines
21. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts
22. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts
23. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
24. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (Human Upstream Binding Factor)
25. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities
26. Cisplatinand UV-damaged DNA lure the basal transcription factor TFIID/TBP
27. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor
28. Kinetics of the reaction of cis-platinum compounds with DNA in vitro
29. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
30. In vitro biotransformations of tetrachloro(d,1-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma
31. Rapid reduction of tetrachloro(d,1-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium
32. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line
33. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells
34. Displacement of the bidentate malonate ligand from (d,1-trans-1,2-diaminocyclohexane)malonatoplatinum(II) by Physiologically important compounds in vitro
35. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin
36. High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand
37. Biotransformations of oxaliplatin in rat blood in vitro
38. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a wistar rat model
39. Neuropathy following ormaplatin administration: Human and laboratory studies
40. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)
41. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats
42. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase-I clinical trial
43. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model
44. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
45. Increased DNA binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: Activation theory revisited
46. Formation of DNA adducts by the anticancer drug carboplatin: Different nucleotide sequence preferences in vitro and in cells
47. Cisplatin and carboplatin-DNA adducts: Is Pt-AG the cytotoxic lesion?
48. Accumulation of cis-diammine-dichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro
49. Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum, L-OHP) with CDDP on various cells: Correlation with intracellular accumulation
50. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel
51. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in Non-Small Cell Lung Cancer (NSCLC) sublines resistant to cisplatin
52. Antitumour activity of oxaliplatin in neuroblastoma cell lines
53. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines
54. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
55. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
56. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
57. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
58. Oxaliplatin: Mechanism of action and antineoplastic activity
59. Intracellular glutathione and cytotoxicity of platinum complexes
60. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers
61. Antitumor activity of L-OHP in mice
62. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): New experimental data
63. Oxalato-Platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
64. Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388
65. Mechanism of the in vitro synergism between SN38 and oxaliplatin
66. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
67. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
68. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line
69. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
70. Clinical pharmacokinetics of oxaliplatin: A critical review
71. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
72. Pharmacokinetics and safety profile of oxaliplatin
73. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
74. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
75. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects
76. Ongoing and unsaid on oxaliplatin: The hope
77. Oxaliplatin: A new therapeutic option in colorectal cancer
78. A Phase I Trial of trans-1-diaminocyclohexane oxalato-platinum (LOHP)
79. Phase I study of oxaliplatin in patients with advanced cancer
80. Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches
81. Oxaliplatin (L-OHP): Global safety in 682 patients (pts)
82. Anaphylactic reaction to oxaliplatin: A case report
83. Oxaliplatin-induced haemolytic anaemia
84. Anaphylaxis after Oxaliplatin
85. Severe anaphylactic reactions to oxaliplatin
86. Allergic reactions to cytotoxic drugs - An update
87. More about irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin
88. Efficacy and toxicity of irinotecan in patients with colorectal cancer
89. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer
90. A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (Pts) with previously untreated metastatic colorectal Cancer (MCC)
91. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (Leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
92. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal
93. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (Pts) with metastatic colorectal cancer (MCC)
94. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU+/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the european compassionate-use program
95. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6) GERCOR
96. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma
97. Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer
98. Addition of oxaliplatin (L-OHP) to chronomodulated (CM), 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC)
99. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics
100. CPT-11/oxaliplatin every two weeks: A phase I study in patients with advanced digestive tumors
101. Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer
102. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal Cancer
103. Clinical trials referral resource. Clinical trials of combination regimens containing oxaliplatin
104. Phase I-II trial and pharmacokinetic analysis of oxaliplatin plus 5-FU/leucovorin plus irinotecan combination in advanced colorectal carcinoma
105. Phase I study of capecitabine in combination with oxaliplatin in patients with advanced metastatic solid tumors
106. Phase II trial of oxaliplatin-Uft-leucovorin combination in first line treatment of advanced colorectal cancer
107. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: Preliminary results of phase I clinical trials
108. Phase I/II dose-finding and pharmacokinetic study of tomudex in combination with oxaliplatin in advanced solid tumors
109. Raltitrexed (Tomudex) and oxaliplatin: An active out-patient regimen in malignant mesothelioma
110. Oxalipaltin+tomudex and levo-folinic acid+fluorouracil every 2 weeks. A dose finding study in advanced colorectal carcinoma
111. Tomudex plus oxaliplatin in previously untreated metastatic colorectal cancer patients: An active combination
112. Raltitrexed in combination treatment for colorectal cancer: New perspectives
113. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations
114. A dose finding and toxicity study of the gemcitabine-oxaliplatin combination in patients with advanced solid tumors
115. Combination therapy with oxaliplatin+gemcitabine in advanced pancreatic cancer
116. Biweekly docetaxel, gemcitabine, coxaliplatin in heavily pretreated patients with solid tumors - Preliminary results of a phase I study
117. A phase I trial of continuous infusion 5-FU and weekly gemcitabine: Updated results of an active combination for renal cell, hepatocellular and colon cancer
118. Gemcitabine (dFdC) affects 5-flurouracil (5-FU) pharmacokinetics in cancer patients
119. A Phase I study of docetaxel and oxaliplatin as frontline treatment in metastatic breast cancer and nonsmall cell lung cancer: Preliminary results
120. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience
121. A phase I study of the multitargetted antifolate (MTA)(LY 231514) in combination with oxaliplatin in metastatic solid tumors
122. Preliminary report on oxaliplatin/navelbine phase I/II multicentric trial in patients with advanced nonsmall cell lung cancer (NSCLC): An active combination
123. Treatment of patients with cisplatin-refractory testicular germ-cell cancer
124. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients
125. Oxaliplatin: In vitro and in vivo evidence of its radiation sensitizing activity - Preclinical observations relevant to ongoing clinical trials
126. DNA adducts from chemotherapeutic agents
127. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
128. Molecular mechanism of nucleotide excision repair
129. Nucleotide excision repair in mammalian cells
130. The MO15 cell cycle kinase is associated with the TFIIH transcription - DNA repair factor
131. Deficient gene specific repair of cisplatin-induced lesions in xeroderma pigmentosum and fanconi's anemia cell lines
132. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in chinese hamster ovary cells
133. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification
134. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy
135. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair
136. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells
137. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
138. Cisplatin sensitivity/resistance in UV repair-deficient chinese hamster ovary cells of complementation groups 1 and 3
139. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line
140. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells
141. Gene expression in x-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity
142. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
143. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours
144. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines
145. The DNA damage-recognition problem in human and other eukaryotic Cells: The XPA damage binding protein
146. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA
147. Life without DNA repair
148. Base excision repair of oxidative DNA damage activated by XPG protein
149. High incidence of ultraviolet-B- or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group a gene
150. HER-2/neu signal transduction in human breast and ovarian cancer
151. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
152. Basic science of HER-2/neu: A review
153. The biology of erbB-2/neu/HER-2 and its role in cancer
154. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
155. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
156. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
157. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
158. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185her2/neu monoclonal antibody plus cisplatin in patients with HER-2/neuOverexpressing metastatic breast cancer refractory to chemotherapy treatment
159. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
160. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations
161. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells
162. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
163. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA
164. Sensitization of HER-2/neu overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin
165. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway
166. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells
167. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
168. A novel function of emodin: Enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells
169. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins
170. Nickel(II) increases the sensitivity of V79 chinese hamster cells towards cisplatin and transplatin by interference with distinct steps of DNA repair
171. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro
172. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy
173. Mixed backbone oligonucleotides targeting the nucleotide excision repair protein XPA potentiate cisplatin cytotoxicity
174. Efficient translesion replication past oxaliplatin and cisplation GPG adducts by human DNA polymerase